SMMT · Company research
Summit Therapeutics Inc. Common Stock (SMMT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) latest stock news and headlines - Yahoo Finance Singapore | Summit Therapeutics Inc. (SMMT) latest stock news and headlines Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 19, 2026 | neutral | 0 | 0.6 |
| A kidney cancer study will test four approaches, including standard care - Stock Titan | A kidney cancer study will test four approaches, including standard care Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits | SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus - Yahoo Finance | Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics Stock Price Forecast. Should You Buy SMMT? - StockInvest.us | Summit Therapeutics Stock Price Forecast. Should You Buy SMMT? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled - TradingKey | Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled TradingKey | View source ↗ | TradingKey | Oct 13, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions - Simply Wall Street | Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics (SMMT) Stock Price, News & Analysis - MarketBeat | Summit Therapeutics (SMMT) Stock Price, News & Analysis MarketBeat | View source ↗ | MarketBeat | Oct 12, 2026 | neutral | 0 | 0.6 |
| Nasdaq Futures Tread Water After Monday Rout: MU, NVTS, NVO, KOD, SMMT, ASTS Stocks In Focus - Stocktwits | Nasdaq Futures Tread Water After Monday Rout: MU, NVTS, NVO, KOD, SMMT, ASTS Stocks In Focus Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill | SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) ChartMill | View source ↗ | ChartMill | Oct 10, 2026 | neutral | 0 | 0.6 |
| SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos | Summit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway across multiple solid tumors, starting with a phase III study in first-line triple-negative breast cancer. This partnership builds on AstraZeneca's $2 billion investment in Summit announced the previous week, expanding ivonescimab's development pipeline and creating additional clinical and commercial opportunities. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.5 | 1 |
| Bernstein reiterates Summit Therapeutics stock rating on trial concerns - Investing.com | Bernstein reiterates Summit Therapeutics stock rating on trial concerns Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet - StocksToTrade | SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet StocksToTrade | View source ↗ | StocksToTrade | Sep 29, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet - Timothy Sykes | SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet Timothy Sykes | View source ↗ | Timothy Sykes | Sep 29, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? - Yahoo Finance | SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? - TradingView | SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? TradingView | View source ↗ | TradingView | Sep 28, 2026 | neutral | 0 | 0.6 |
| $SMMT stock is down 5% today. Here's what we see in our data. - Quiver Quantitative | $SMMT stock is down 5% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 28, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? - Yahoo Finance | Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 27, 2026 | neutral | 0 | 0.6 |
| Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade) (NASDAQ:SMMT) - Seeking Alpha | Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade) (NASDAQ:SMMT) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 26, 2026 | neutral | 0 | 0.6 |
| Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits | Why Is SMMT Stock Surging Over 10% In Overnight Trading? Stocktwits | View source ↗ | Stocktwits | Jun 1, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.